Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. Its lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. The company also markets DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a life-threatening complication of lymphoma, a cancer of the immune system. Its development pipeline comprises DepoMeloxicam, a long-acting non-steroidal anti-inflammatory drug, which is in preclinical development for the treatment of acute postsurgical pain; and DepoTranexamic Acid, a pre-clinical development product for the treatment or prevention of excessive blood loss during surgery by promoting hemostasis. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010.

Parsippany-Troy Hills, US
Size (employees)
487 (est)
Pacira Pharmaceuticals was founded in 2006 and is headquartered in Parsippany-Troy Hills, US

Pacira Pharmaceuticals Office Locations

Pacira Pharmaceuticals has offices in Parsippany-Troy Hills, Jersey, New York, Washington and in 2 other locations
Parsippany-Troy Hills, US
Washington, US
New York, US
San Diego, US
San Diego, US

Pacira Pharmaceuticals Metrics

Pacira Pharmaceuticals Summary

Market capitalization

$1.71 B

Closing share price

Pacira Pharmaceuticals's current market capitalization is $1.71 B.

Pacira Pharmaceuticals Financials

Pacira Pharmaceuticals's revenue is $249 M in FY, 2015 which is a 25.97% increase from the previous period.
FY, 2015FY, 2014FY, 2013


$249 M$198 M$85.6 M

Revenue growth, %


Gross profit

$177 M$120 M$30.8 M

Operating income

$9.46 M$-5.17 M$-53.3 M

Operating expense total

$240 M$203 M$139 M

Net Income

$1.86 M$-13.7 M$-63.9 M

Operating cash flow

$19.5 M$25 M$2.39 M

Pacira Pharmaceuticals Market Value History

Pacira Pharmaceuticals Company Life